|, The plaintiffs, Elaine and Gerald De-roche, appeal a summary judgment dismissing their medical malpractice action against the defendant, Rian M. Tanen-baum, M.D., with prejudice. For the following reasons, we affirm.
I.
On 16 January 2008, Elaine Deroche filed a complaint with the Louisiana Patients’ Compensation Fund (“LPCF”) alleging that Dr. Tanenbaum, a gastroen-terologist, deviated from the prevailing standards of care when he ordered her to follow the instructions prepared by Metropolitan Gastroenterology Associates
| gElaine Deroche was initially treated by Dr. Tanenbaum in 1998 for irritable bowel syndrome.
Mrs. Deroche returned to Dr. Tanen-baum on 28 January 2007 upon referral by her family physician following complaints of blood-tinged diarrhea. Blood work performed by the referring physician the previous day indicated Mrs. Deroche was not dehydrated at that time. Given her history of loose bowels for approximately three weeks duration, Dr. Tanenbaum recommended and had his staff schedule Mrs. Deroche for a colonoscopy for 7 February 2007 to take place at MGA’s facilities. According to Dr. Tanenbaum, because Mrs. Deroche had used the same FPS prep prior to her 2004 colonoscopy and done very well with it, he determined that the FPS prep would likewise be an appropriate bowel preparation for her colonoscopy in 2007. Dr. Tanenbaum discussed the procedure with Mrs. Deroche, explained why he was recommending she undergo the procedure, and explained what she needed to do in preparation for the procedure, including utilizing the FPS prep.
Mrs. Deroche was given written instructions prepared by MGA that provided a step-by-step process for using the FPS prep that she was to complete during the days immediately preceding her scheduled colonoscopy.
pin her deposition, Mrs. Deroche testified that she purchased a single three-ounce bottle of FPS prep, but did not read or retain the package insert. She claimed that after measuring half of the bottle and mixing it with apple juice, she took the first dose at 6:00 a.m. on the morning of the procedure, which caused her to immediately regurgitate. She explained that due to her nausea and vomiting, she was unable to drink the required eight ounces of liquid following the first dose as directed.
Mrs. Deroche testified that she telephoned Dr. Tanenbaum’s office at MGA to report having vomited the first dose and left a message with MGA’s answering service.
It is undisputed that Dr. Tanenbaum was not notified at any time prior to performing Mrs. Deroche’s colonoscopy — by Mrs. Deroche or anyone else — that she was nauseous, had vomited the morning of the procedure, or that she had taken | sboth doses of the FPS prep within 30 minutes of one another without hydration in-between doses contrary to the written instructions.
According to Dr. Tanenbaum, Mrs. De-roche’s colonoscopy was performed under moderate sedation without complications. He did not find any abnormalities; to the naked eye, the colon looked completely normal. Biopsies were obtained for further analysis.
On the day following the procedure, Mrs. Deroche experienced difficulty urinating. She contacted Dr. Tanenbaum’s office and was instructed to go to the hospital. She presented to the emergency room at West Jefferson Medical Center and was thereafter admitted to the hospital with a diagnosis of dehydration and, based on elevated blood urea nitrogen (BUN) and creatinine levels, acute renal failure and nephrocalcinosis.
The Deroches filed a complaint with the LPCF in January 2008
|7The Deroches subsequently filed the instant state court action against Dr. Tanenbaum, MGA, and Fleet in March 2012. Specifically, the Deroches’ petition alleged that Dr. Tanenbaum deviated from the prevailing standard of care for gas-troenterologists in providing medical care to Mrs. Deroche when he negligently: (1) failed to determine if Mrs. Deroche was dehydrated prior to instructing her to take the FPS prep; (2) failed to inform her of the potential risk of nephrotoxicity associated with taking the FPS prep; (3) instructed her to use the FPS prep contrary to the instructions and warnings provided by Fleet; and (4) advised Mrs. Deroche to immediately take the second dose of FPS despite her having regurgitated after ingesting the first dose. The plaintiffs further averred that Mrs. Deroche’s acute renal failure and nephrocalcinosis was directly caused by Dr. Tanenbaum’s breach of the applicable standard of care.
Dr. Tanenbaum and MGA answered the plaintiffs’ petition. In November 2012, they moved for summary judgment seeking dismissal of the Deroches’ claims on the basis that the plaintiffs failed to identify any expert medical witness to establish the applicable standard of care and/or to establish their claim that Dr. Tanenbaum’s actions deviated from that standard of care causing Mrs. Deroche’s acute renal failure. In support of his motion for summary judgment, Dr. Tanenbaum submitted a copy of the expert opinion of the medical review panel
1. There was no reason to suspect the patient was dehydrated prior to [taking] the [FPS] prep.
|82. The patient did not have any contraindications for the use of Fleet Phospho-Soda prep.
3. The prescribed prep was within the variations that were considered appropriate at the time of this procedure.
4. While disputed as to whether there was a telephone call, the panel finds that it was appropriate to let the patient take a second dose of Fleet Phospho-Soda prep after immediately vomiting the first dose.
In further support of his motion, Dr. Tanenbaum attached a copy of MGA’s written instructions for the colonoscopy preparation with FPS prep; a copy of Mrs. Deroche’s deposition; excerpts from the deposition of Dr. J. Kevin Modisette, Mrs. Deroche’s treating nephrologist;
Mrs. Deroche’s deposition testimony established that she had used a bowel cleansing prep prior to her colonoscopy in 2004 without incident and about which she had no complaints. According to Dr. Tanen-baum, the prep Mrs. Deroche used in 2004 colonoscopy was the same FPS prep he instructed her to use in preparation for her 2007 colonoscopy. Mrs. Deroche’s deposition testimony further established that prior to her colonoscopy in 2007, Dr.
The deposition testimony of Dr. Modi-sette supports Dr. Tanenbaum’s contention that the instructions given to Mrs. De-roche prior to her colonoscopy regarding the use of FPS prep were appropriate. Specifically, Dr. Modisette testified as follows:
Q. Do you have any criticism of the instruction to the patient to drink a quart of green Gatorade on Monday, another quart of green Gatorade on Tuesday, and on Wednesday to take half a bottle, one and a half ounces of Fleet Phospho-Soda mixed with a four-ounce glass of clear liquid, followed up with a full glass of eight-ounce clear liquid and then waiting three hours for the second half of the dose?
A. No. That seems to be actually more appropriate than the company recommendations based on what I’ve read. That is a low dose prep and it sounds like if she was, in fact, told to drink that much Gatorade, they were trying to protect against dehydration.
In opposition to Dr. Tanenbaum’s motion, the Deroches submitted a photocopy of the affidavit of Dr. Karen Kim, an expert retained by Fleet to defend against the prior product liability action the Der-oches brought against Fleet in federal court, which action was dismissed in 2009.
Dr. Tanenbaum’s motion for summary judgment came for hearing in January 2013, nearly five years from the date the Deroches’ instituted their initial claim against Dr. Tanenbaum with the LPCF. Following oral argument, the trial court granted Dr. Tanenbaum’s motion, without written reasons, dismissing the Deroches’ suit against him with prejudice.
The Deroches’ timely filed a motion to set aside the judgment and for new trial. In support of their motion, the plaintiffs again attached a photocopy of the affidavit of Dr. Kim, in addition to the deposition of Dr. Tanenbaum, a copy of the PDR’s instructions and warnings for FPS prep, a copy of Dr. Tanenbaum’s instructions for colonoscopy preparation with FPS- prep, and various medical records of Mrs. De-roche. The motion was orally argued before the trial court on 22 March 2013, and
The Deroches perfected this appeal, arguing that issues of fact remain as to whether they have satisfied their burden under La. R.S. 9:2794 by demonstrating that Dr. Tanenbaum deviated from the applicable standard of care when he failed to use reasonable care and diligence in his treatment of Mrs. Deroche, and as to whether his breach caused Mrs. Deroche to sustain acute renal failure.
II.
An appellate court utilizes a de novo standard to review the granting or denial of a motion for summary judgment. Independent Fire Ins. Co. v. Sunbeam Corp., 1999-2181, p. 7 (La.2/29/00),
The burden of proof is on the movant. But if the movant will not bear the burden of proof at the trial of the matter, the movant is not required to negate all essential elements of the adverse party’s claim, but rather to point out an absence of factual support for one or more essential elements. Thereafter, if the adverse party fails to provide factual evidence to establish that he will be able to satisfy his evidentiary burden of proof at trial, no genuine issue of material fact exists, and summary judgment is properly granted. La. C.C.P. art. 966 C(2).
In a ruling on a motion for summary judgment, the trial court’s role is not to evaluate the weight of the evidence or to determine the truth of the matter, but instead to determine whether a genuine issue of triable fact remains. Hines v. Garrett, 04-0806, p. 1 (La.6/25/04),
La. R.S. 9:2794 A provides that a plaintiff in a medical malpractice action against a physician bears the burden of proving by a preponderance of the evidence: (1) the applicable standard of care expected of physicians in his medical specialty, (2) a violation of that standard of care, and (3) a causal connection between the alleged negligent treatment and the plaintiffs injuries resulting | ^therefrom. Pfiffner v. Correa, 94-0924, 94-0963, 94-0992, p. 8 (La.10/17/94),
In the instant case, Dr. Tanenbaum does not dispute that Mrs. Deroche sustained acute renal failure and nephrocalci-nosis following the colonoscopy he per
The Deroches argue that Dr. Tanen-baum’s own deposition testimony raises an issue of fact as to whether he breached the standard of care of gastroenterologists. Specifically, the Deroches contend that because of Mrs. Deroche’s history of several weeks of persistent diarrhea, Dr. Tanen-baum should have ordered another blood test immediately prior to performing the colonoscopy to ensure that she was properly hydrated. According to the Deroches, pursuant to Fleet’s instructions for the FPS prep, “in patients such as Mrs. De-roche,” a baseline 113and post-treatment sodium, potassium, chloride, bicarbonate, phosphate, blood urea nitrogen, and creati-nine values should have been obtained. The plaintiffs apparently seek to have us infer a breach of the applicable standard of care from Dr. Tanenbaum’s failure to conduct an additional blood test prior to Mrs. Deroche’s colonoscopy in order to obtain her baseline electrolyte levels. The plaintiffs posit that other than Dr. Tanenbaum’s deposition testimony, no additional expert testimony is needed to support their contention that Dr. Tanenbaum’s reliance on the previous doctor’s blood work rather than performing his own constituted negligence resulting in Mrs. Deroche’s acute renal failure.
Though conceding the importance of obtaining a baseline electrolyte level in an at-risk patient before prescribing FPS prep, Dr. Tanenbaum does not dispute that he relied on the blood work of the referring physician instead of conducting his own blood test before proceeding with Mrs. Deroche’s colonoscopy. According to Dr. Tanenbaum, the “at-risk” population associated with the FPS prep was identified to include those patients with pre-existing kidney disease, congestive heart failure, colitis, and patients that were on certain types of medications such as diuretics or ace inhibitors. Contrary to the unsubstantiated assertions by the plaintiffs that Mrs. Deroche fell into this “at-risk” category, in Dr. Tanenbaum’s medical opinion, her ongoing bowel issues did not place her “at-risk” such that additional blood work was necessary. Consequently, Dr. Tanenbaum argues that his reliance on the referring physician’s blood work was proper, and no reason existed for him to believe Mrs. Deroche was dehydrated prior to his performing the colonoscopy.
Next, the plaintiffs claim that Dr. Tanenbaum breached the applicable standard of care by failing to inform Mrs. Deroche of the potential risk of nephrotox-icity and/or acute renal failure associated with taking the FPS prep. The plaintiffs present no expert medical testimony to establish this aspect of their claim. The record contains a consent form executed by Mrs. Deroche disclosing the risks associated with a colonoscopy, which included the loss of function of an organ. It is undisputed that Mrs. Deroche experienced acute renal failure, or loss of kidney function, following her colonoscopy.
The second prong of the materiality test requires proof that a reasonable person in the patient’s position would have attached significance to the risk in deciding whether or not to forgo the proposed treatment. Id. at 412. While this determination of materiality does not require expert testimony, our review of the summary judgment evidence indicates that the plaintiffs cannot carry their burden. The record establishes that Mrs. Deroche used the same FPS prep without incident prior to her colonoscopy in 2004. Consequently, absent evidence to the contrary, it reasonably follows that even had Dr. Tanenbaum informed her of the potential for the rare risk of renal failure to occur she, or a reasonable person in her position, would not have withheld consent to use of the FPS prep. Accordingly, we reject the plaintiffs’ argument that Dr. Tanenbaum breached the applicable standard of |17care by failing to inform Mrs. Deroche of the rare risk of renal failure associated with use of FPS prep.
The Deroches next argue that Dr. Tanenbaum breached the standard of care by providing Mrs. Deroche outdated instructions that were contrary to Fleet’s directives and warnings regarding the taking of FPS prep. Offering no expert medical testimony, the plaintiffs refer to the PDR’s instructions and warnings for FPS prep to support their position.
The medical review panel rejected the plaintiffs’ contention and, absent expert medical testimony to the contrary, so do we. We specifically hold that a manufacturer’s labeling and package insert standing alone is insufficient to establish the prevailing medical standard of care required by La. R.S. 9:2794. Similarly, we find that a physician’s medical decision to deviate from a manufacturer’s labeling also does not ipso facto establish a breach of the applicable standard of care.
The plaintiffs aver that the affidavit of Dr. Kim, a gastroenterologist, fur
The absence of expert medical testimony in this case to support the plaintiffs’ various theories of liability against Dr. Tanen-baum is the death knell of the Deroches’ claims against him. Reviewing the record de novo, we find the evidence adduced by the plaintiffs is insufficient to prove the applicable standard of care, its breach, or causation. Summary judgment dismissing their claims was proper.
III.
For the reasons assigned, we affirm the judgment of the trial court.
AFFIRMED.
Notes
. MGA is the medical group with whom Dr. Tanenbaum practices medicine.
. Fleet Phospho-Soda is manufactured and distributed by C.B. Fleet Company (“Fleet”), which is also a defendant in the instant litigation.
. Mrs. Deroche’s complaint with the LPFC further averred that MGA breached the prevailing standard of care when one of its nurses improperly advised her to ingest a second dose of the FPS prep on the morning of the procedure, which allegedly caused her to sustain permanent kidney damage. MGA moved for summary judgment, which motion was denied. Thus, the Deroches’ allegations asserted against MGA are not currently before the court on this appeal.
. At that time, Mrs. Deroche underwent a flexible sigmoidoscopy, a procedure used pri- or to colonoscopies, performed by Dr. Tanen-baum, which revealed a "mild inflammatory reaction of the colon.” Based upon this finding, Dr. Tanenbaum diagnosed Mrs. Deroche as suffering from irritable bowel syndrome.
. Dr. Tanenbaum described a colonoscopy as "an evaluation of the large intestine with an endoscopic or a fiber-optic scope to aid in evaluation and treatment of the patient.”
. The record contains a "Consent for Medical Procedure and Acknowledgement of Receipt of Information” executed by Mrs. Deroche prior to undergoing the colonoscopy.
. Dr. Tanenbaum testified that, while he was aware of the risk of acute renal failure associated with the use of the FPS prep, he did not discuss the possibility with her because, in his medical opinion and based upon Mrs. De-roche's prior use of the same prep without incident, he believed Mrs. Deroche was not a part of the at-risk population, especially had she followed the MGA written instructions and been properly hydrated during the course of the preparation for the colonoscopy.
. Dr. Tanenbaum explained that the protocol or written instructions for the FPS prep given to Mrs. Deroche were drafted by MGA based on recommendations from various medical
. It is undisputed that the instructions for taking the FPS prep prepared by MGA differed from Fleet's instructions and warnings regarding the use of the FPS prep that were in effect at the time of Mrs. Deroche’s colo-noscopy. Specifically, instead of the three-hour lapse between the first and second doses espoused by Dr. Tanenbaum and MGA, Fleet recommended ten to twelve hours between doses. Dr. Tanenbaum admitted in his deposition that he was unaware of Fleet's revisions to its instructions regarding the change in the timeframe. Despite the Fleet package instructions, however, Dr. Tanenbaum was of the medical opinion that the three-hour span for taking the preparation was sufficient and appropriate.
. Whether Mrs. Deroche actually made the call to MGA and eventually spoke with a MGA nurse remains a fact in contention. But this unresolved factual issue is not relevant to the issues regarding the alleged negligence or malpractice of Dr. Tanenbaum. MGA’s motion for summary judgment, which is not before this court on appeal, was denied on this basis.
. Mrs. Deroche's biopsy report later revealed a diagnosis of "collagenous colitis,” which Dr. Tanenbaum explained is a microscopic colitis that cannot be detected with visualization of the colon, but only by biopsy.
. In her deposition, Mrs. Deroche testified that following the procedure, she specifically recalls being told to drink plenty of fluids that evening.
. Nephrocalcinosis is a condition in which calcium levels in the kidneys are increased.
. Also in January 2008, after filing their complaint with the LPCF, the Deroches filed a product liability action against Fleet in federal court alleging that the FPS prep was unreasonably dangerous and caused Mrs. Deroches’ acute kidney failure. In January 2009, Fleet filed a motion for summary judgment, seeking dismissal of the Deroches' claims on the basis that they failed to present any medical expert testimony to prove them. On 18 February 2009, the Deroches moved to voluntarily dismiss their claims against Fleet without prejudice.
. The complaint also alleged that MGA breached the applicable standard of care resulting in Mrs. Deroche’s acute renal failure and nephrocalcinosis.
. The medical review panel consisted of Drs. James Smith, John Harrington, and Sean Connolly.
. A nephrologist is a medical doctor who specializes in kidney care and diseases.
. Mrs. Deroche testified that because of her nausea, she was unable to drink the requisite eight ounces of fluid following the first dose of the FPS prep.
. Notably, Dr. Kim was retained by Fleet as its expert in the earlier federal product liability action to discuss Fleet’s compliance with FDA regulations and the safety of its product, and whether Fleet properly informed the medical community of the risks and benefits of their product and its subsequent labeling changes.
. Dr. Tanenbaum testified in his deposition as follows:
Q. Would it be fair to say [sic] you, based on your experience of doing these colonos-copies and instructing people to take these difference types of bowel preps, you knew that before 2007, specifically that you don’t want to give this product Fleet Phospho-Soda to somebody that’s dehydrated?
A. Yes.
Q. If you had information that the patient was possibly dehydrated, that would be the appropriate protocol to do before giving them this Fleet product, do a baseline blood test on them?
A. Yes.
Q. Did you do a baseline blood test on Ms. Deroche before giving her this product Fleet Phospho-Soda?
A. Yes.
Q. You did?
A. The doctor that saw the patient before I did did a baseline.
Q. I saw that in the medical records. If you can find that in the records for me, do you know the date that was given?
A. January 22, 2007.
Q. The actual colonoscopy was on February 7, 2007, correct?
A. Yes.
Q. So we’re taking approximately, what, two weeks?
A. Yes.
Q. Can someone get dehydrated within a two-week period?
A. If you’re asking me if the patient had a change in her symptoms, which she had for three weeks prior to seeing me and her blood work did not show dehydration, the patient at the time of the procedure did not notify me of any changes of those symptoms, the answer is that the baseline on 1/22 would suffice.
Q. So diagnostically we don’t know if she was dehydrated or not back in February 7, 2007?
A. A blood test was performed on the 22nd of 2007 after the patient had been having several weeks of diarrhea documenting whether the patient would have been having any dehydration from her symptoms which had not changed and the patient did not let me know that at the time of her colonoscopy.
. In Louisiana, an executed consent form presents a presumption of informed consent, which may be rebutted by proving the following: (1) a material risk exists which the physician has a duty to disclose; (2) the physician failed to information the patient about a material risk; (3) the material risk was realized; and, (4) a causal connection exists between the failure to inform the patient of the risk and realization of the risk. See Hondroulis v. Schuhmacher,
. The instructions Dr. Tanenbaum provided to Mrs. Deroche directed her to take the second dose of the FPS prep three hours after ingesting the first dose. Fleet's instructions recommend 10 to 12 hours between doses.